Latest post

Although Lung Cancer Remains Grim Diagnosis Scientists See Hope In Progress Being

first_img St. Louis Public Radio: Siteman Aims To Make Clinical Trials More Diverse By Bringing Science To North St. Louis It was several months after learning she had a rare brain tumor — and several more before she would turn 13 — when Lola Muñoz drove from Upstate New York to Tennessee with her mother. The choice had been Lola’s: to enter a clinical trial testing whether two chemotherapy drugs might be safe for patients with DIPG. Diffuse intrinsic pontine gliomas, striking in childhood at the base of the brain, are especially aggressive, difficult to treat and deadly. Lola opted to take part in the trial at St. Jude Children’s Research Hospital in Memphis with a singular hope. “I’d rather help find something for the other kids that will get DIPG than to not help at all,” she explained. (Levine, 6/4) Cancer researchers presented more evidence of advances against one of the deadliest and most common forms of the disease—lung cancer—at a major medical meeting here. Studies released at the annual meeting of the American Society of Clinical Oncology in recent days showed that a range of newer approaches, from immune-boosting drugs to treatments targeting genetic traits of tumors, can help patients. Some of the drugs are supplanting or augmenting chemotherapy, which has been commonly used to treat lung cancer for years but with limited effectiveness. (Loftus, 6/4) The Washington Post: Live Like Lola: A Young Girl Confronts Deadly Brain Cancer With Resolve President Donald Trump is expected to sign into law soon a bill meant to enhance research into childhood cancers and their treatments. Groups who push for progress against childhood cancer see this as a significant win after they grew frustrated with Congress and the administration’s pursuit of higher-profile legislation to expand access to experimental treatments. The bill (S 292) Trump plans to sign would let the Health and Human Services Department set up demonstration projects for childhood cancer survivors. Even after successful treatment, these patients can experience effects from their cancer, such as cardiovascular issues, intellectual handicaps and emotional trauma. (Siddons, 6/5) One of the big questions facing women with early-stage breast cancer is whether to be treated with chemotherapy to reduce their risks that the cancer will return. A new study presented Sunday at the annual meeting of the American Society of Clinical Oncology provides much-needed clarity: Most of these women can safely skip chemo. Although chemotherapy for early-stage breast cancer has been declining, physicians said the latest research findings will have a major effect by either giving patients more confidence in their decisions or encouraging them to take a different treatment approach. There are some important nuances, however. (McGinley, 6/4) CQ HealthBeat: Groups Cheer Child Cancer Bill After Doubts Over ‘Right To Try’ The Wall Street Journal: Research Yields Progress Against Lung Cancer The Washington Post: A Big Question Answered About Treating Early-Stage Breast Cancer center_img Countless breast cancer patients in the future will be spared millions of dollars of chemotherapy thanks in part to something that millions of Americans did that cost them just pennies: bought a postage stamp. Proceeds from the U.S. Postal Service’s breast cancer stamp put researchers over the top when they were trying to get enough money to do the landmark study published on Sunday that showed genetic testing can reveal which women with early-stage breast cancer need chemo and which do not. (Marchione, 6/4) This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription. The Associated Press: Licking Cancer: US Postal Stamp Helped Fund Key Breast Study Los Angeles Times: For Many Lung Cancer Patients, Keytruda Is A Better Initial Treatment Than Chemotherapy, Study Finds In findings that may allow many lung cancer patients to avoid chemotherapy, a large clinical trial has shown that the immunotherapy drug Keytruda is a more effective initial treatment for two-thirds of patients with the most common type of lung cancer. Compared with advanced small-cell lung cancer patients who got chemotherapy, those treated first with Keytruda had a median survival time that was four to eight months longer. (Healy, 6/5) Although Lung Cancer Remains Grim Diagnosis, Scientists See Hope In Progress Being Made “The era in which chemotherapy was the only option for non-small-cell lung cancer patients is drawing to a close,” said John Heymach, a lung-cancer specialist at the University of Texas MD Anderson Cancer Center. Researchers touted new treatment such as immune-boosting drugs and procedures targeting genetic traits of tumors. More oncology news focuses on breast cancer, a child cancer bill, a young girl with a brain tumor, and more. To help increase diversity in its cancer studies, Siteman bringing the science to people’s neighborhoods, with smaller centers in traditionally underserved areas, far away from the big medical campus. … While the gap is closing, fewer than 10 percent of cancer clinical trial participants are African-American. (Fentem, 6/4) last_img read more

Donald Trump is suing Deutsche Bank Capital One to stop them from

first_img Join the conversation → Donald Trump poses with his children Don Trump Jr., left, Ivanka and Eric at a ribbon cutting ceremony of the Trump International Hotel and Tower at Toronto in 2012.Ernest Doroszuk/Postmedia Bloomberg News Email April 30, 20197:36 AM EDT Filed under News FP Street Twitter Facebook What you need to know about passing the family cottage to the next generation advertisement Peter Blumberg and Robert Burnson Sponsored By: President Donald Trump sued to block Deutsche Bank AG and Capital One Financial Corp. from complying with congressional subpoenas targeting his bank records, escalating the president’s showdown with Democratic lawmakers investigating his finances.The German lender has already begun the process of giving documents related to loans made to Trump or some of his businesses to the New York state attorney general, who is conducting her own probe, said a person familiar with the matter. The bank hasn’t yet handed over any client-related records to the House committees and will wait for the outcome of the legal proceedings, said the person, asking not to be identified in disclosing internal information.“The subpoenas were issued to harass President Donald J. Trump, to rummage through every aspect of his personal finances, his businesses, and the private information of the President and his family, and to ferret about for any material that might be used to cause him political damage,” Trump’s lawyers wrote in the introduction to the 13-page complaint filed Monday in Manhattan federal court.Joining Trump as plaintiffs were his eldest children, Donald Jr., Eric and Ivanka Trump, as well as the Trump Organization, the Donald J. Trump Revocable Trust and other entities affiliated with the president’s family.House Democrats’ investigations into President Trump’s finances and potential money laundering tied to Russia have prompted them to demand documents from nine banking giants, according to people familiar with the matter. Deutsche Bank, which lent Trump some US$340 million, has been a primary target of the House Financial Services Committee, led by Representative Maxine Waters.Both Waters and House Intelligence Chairman Adam Schiff have been seeking information from Deutsche Bank since Democrats took over the House majority in January. Schiff said the Frankfurt-based bank has been cooperative with the investigations and their request was a “friendly subpoena.” Such a subpoena is typically submitted when a firm is willing to hand over documents but wants a formal request first.Related Stories:U.S. appeals court judges spar with Trump lawyer over bid to block House subpoenaExit of Deutsche Bank’s investment bank chief marks end of eraAfter Deutsche Bank cuts, where will the growth be?“We remain committed to providing appropriate information to all authorized investigations and will abide by a court order regarding such investigations,” a Deutsche Bank spokesman said in a statement on Tuesday.Deutsche Bank had been Trump’s go-to lender for decades, even as other commercial banks stopped doing business with him because of multiple bankruptcies. Although the German lender’s investment bank had severed ties with Trump during the financial crisis, after he defaulted on a loan and then sued the bank, its wealth management unit continued to extend him credit.The firm has stopped doing new business with Trump while he is president, a person briefed on the matter said previously.The complaint is very similar to one Trump filed last week in Washington to block Elijah Cummings, the Maryland Democrat who chairs the House Committee on Oversight and Reform, from getting records held by Trump’s longtime accounting firm Mazars USA LLP.The new case is Trump v. Deutsche Bank, 19-cv-03826, U.S. District Court, Southern District of New York (Manhattan).With assistance from Steven ← Previous Next → Comment Recommended For YouU.S. FDA approves Karyopharm Therapeutics’ blood cancer drugOntario Cannabis Store pulls affected CannTrust products amid Health Canada probeUPDATE 2-FDA approves expanded label for Regeneron/Sanofi’s DupixentTrump pick for Fed seat says doesn’t want to pull rug from under market -CNBCAP Explains: US sanctions on Huawei bite, but who gets hurt? Share this storyDonald Trump is suing Deutsche Bank, Capital One to stop them from handing over his finances Tumblr Pinterest Google+ LinkedIn Featured Stories Reddit More Donald Trump is suing Deutsche Bank, Capital One to stop them from handing over his finances Deutsche had been Trump’s go-to lender for decades, even as other banks stopped doing business with him 1 Commentslast_img read more

Tesla transfers energy support division away from Utah

The Tesla rumor mill was firing on all cylinders after some employees reported being fired from the company Draper’s offices.All kind of speculation from hundreds of workers being fired to Tesla shutting down its energy division spread on social media.But the company states that it is only transferring its energy support division away from Utah – affecting about 100 employees. more…The post Tesla transfers energy support division away from Utah appeared first on Electrek. Source: Charge Forward read more

How Formula Es New Era Has Shaken Up The Order

first_imgPre-season testing for Formula E’s fifth season took place at Valencia last week. Not only did we get a good look at the new Gen2 cars in public action for the first time, but suggestions pointed to a possible shake-up in the competitive order. 2Jean-Eric VergneDS Techeetah1m17.342s 9Stoffel VandoorneHWA1m18.032s 5Venturi18 laps1m23.972* 8Mitch EvansJaguar Racing1m17.864s 5Virgin28 laps1m24.855s 10DS Techeetah23 laps1m25.415s 8Jaguar32 laps1m25.348s 2Audi29 laps1m23.900s 1NIO27 laps1m23.499s 4Sebastien BuemiNissan e.dams1m17.473s 10Robin FrijnsVirgin Racing 1m18.088s 5Lucas di GrassiAudi1m17.535s 6HWA15 laps1m23.990s* 2Audi33 laps1m24.015s 9Virgin26 laps1m24.502s 11Tom DillmannNIO1m18.217s 4Mahindra12 laps1m24.371s 11Dragon12 laps1m25.688s 7BMW28 laps1m24.161s 1NIO27 laps1m23.499scenter_img 8Jaguar28 laps1m24.355s 9Venturi19 laps1m25.357s 1Antonio Felix da CostaBMW Andretti1m16.977s 4DS Techeetah21 laps1m23.971s *Run consisted of slow laps followed by flying effortsValencia is absolutely not an FE street-track. The chicane installed three-quarters of the way down the circuit’s main straight was tighter and more acute than most on the calendar – so much so that as well as Griffiths, several team bosses immediately ordered their drivers to take absolutely no chances with the walls and risk damaging the cars with spare parts limited at this stage of the season.Jérôme d’Ambrosio, Mahindra Racing, M5 Electro, Mitch Evans, Panasonic Jaguar Racing, Jaguar I-Type 3Photo by: Andrew Ferraro / LAT ImagesThe drivers didn’t like it – and evidence of its lack of suitability was evidenced by the worn (non-existent) grass at the exit by the end of the week as they had to put wheels over the line to straighten up and hit the power – but it wasn’t changing.Track limits were also widely abused to gain lap time, which is fair enough, it is a test and a tedious subject to drone on about in any case. Then there was the weather interfering on the final day, and even though it did dry out for Friday afternoon, a plague of red flags descended. The running on day two was also compromised due to a ‘race’ simulation (more on that later), which ate into the time available to conduct long runs. Plus there were the reliability dramas that struck many of the teams.So, what can we deduce? With an average new FE race length – 45 minutes plus one lap – thought to be in the region of 34 laps at Valencia, only two squads got close to that: Audi and Jaguar. But NIO, BMW and Virgin Racing were also not too far off and it is NIO’s run on day one – with only one lap featuring the higher 225kW mode – that really stands out. Mahindra and HWA appear to be in the ballpark, but their stints were over a much shorter distance.Best average long runs 3Mahindra11 laps1m23.939s* 3BMW28 laps1m24.161s 10Nissan17 laps1m24.778s 3Jerome D’AmbrosioMahindra Racing1m17.431s *Same run as previous table with outliers removedNow the interesting part. On Friday afternoon – after the track had dried – Audi, DS Techeetah, BMW and Virgin all attempted race stints. Factoring these runs into the best average run times, there are several things to note.First, Lucas di Grassi’s pace did not improve much compared to his mammoth 33-lap run on the morning of day two, which gives us an indication that Audi does not lose pace approaching the end of a full race distance. Second, over 21 laps, DS Techeetah is right with Audi (Andre Lotterer’s average here was much faster than over the 23 laps he did first on Friday afternoon), with BMW just a fraction behind based on Sims’s 28-lap run.Engineer of Sam Bird, Envision Virgin Racing, Audi e-tron FE05Photo by: Dom Romney / LAT ImagesVirgin, which struggled with setting up its Audi-powered cars during the test, was further behind – although taking a look at Sam Bird’s run that was just two laps shorter than Robin Frijns’s longest stint for the team all week, reveals more impressive pace. Bird did an 18-lap stint at 1m24.200s on Wednesday morning, but this was over a considerably shorter distance.Jaguar is in this region too, with Mitch Evans’s time over 29 laps – once a slow first tour has been removed – the best it achieved over long distances in the test.Nissan appears to be slightly further back based on these calculations, although Sebastien Buemi went faster over 17 laps compared to Oliver Rowland over 21 on the final afternoon. At the bottom end, Dragon’s longest run of the week consisted of Antonio Fuoco alternating between backing off and then setting a flying lap, with Jose Maria Lopez’s quickest average over 12 laps containing wildly fluctuating times.With BMW topping the outright pace charts and being right in there on the long-run averages, Audi – last season’s best package thanks to the efficiency advantage it enjoyed over its rivals – thinks its fellow German manufacturer is the team to beat.“I would say there’s been a little bit of convergence in that we made a big step from season three to season four and we’ve made a step from season four to season five, but I think everybody has made a fair old jump forward,” said Audi team principal Allan McNish.Allan McNish, Team Principal, Audi Sport Abt Schaeffler, talks with Sylvain Filippi, Managing Director & CTO, Virgin RacingPhoto by: Alastair Staley / LAT Images“Overall, if I take a global view, BMW have made a big step – that’s fact. They’re quick at all occasions – that’s the way that I look at them, short-run, long-run, medium run – they seem to be quite quick. For me right now, BMW is the one that we look at and they’re the one we’re going to be chasing as a principal point.”Di Grassi has a similar view. Put simply, he reckons Audi’s advantage is gone. “The car is quite good,” says the 2016/17 champion. “The drivetrain is maybe the top three or four, but it’s not as good as last year, the difference [over the opposition].“Last year we had a good advantage, especially in the second half of the season. But this year, it’s going to be super close – everybody’s upped their game.”As can be seen in the adjusted averages – and in the Wednesday non-race ‘race’ – DS Techeetah is in the mix with BMW and Audi. Last season’s runner-up in the teams’ standings, which ran Jean-Eric Vergne to the drivers’ championship, is now enjoying the vast resources of a manufacturer. It looks set for another strong campaign.“I don’t think it’s going to change dramatically from last year,” says team boss Mark Preston regarding the efficiency-vs-pace outlook. “Most of the manufacturers have got quite close to the peaks anyway, but there’s always incremental gains – I’m sure we’re making incremental gains in the background, and they definitely won’t disappear, they’ll keep coming all the time.”Oliver Turvey, NIO Formula E Team, NIO Sport 004Photo by: Dom Romney / LAT ImagesLooking at their long-run pace, NIO and Venturi could well spring surprises. NIO flattered to deceive in season four after topping the fastest times in testing. It’s gone the other way this year with the slowest outright time, but Tom Dillmann’s day-one afternoon race run comfortably tops the averages. NIO only did one race run per driver, with Dillmann’s effort also being its best average – and Oliver Turvey down to a 1m24.144s over 22 laps also on Tuesday afternoon. So, if NIO can reach the pace in qualifying, Dillmann and Turvey should be right in there come the races.“There’s a good degree of confidence,” says team principal Gerry Hughes. “[But] we only know where we are. There’s no specific objective different from [testing] last year.”Venturi’s longest run is on the short side for a confident prediction that it will be in the mix, but given the team had reliability battles in Spain – as did its customer outfit HWA – it gets the benefit of the doubt. Plus, the team was another picked out by many as having made a big improvement from last season. Its best run remained Edoardo Mortara’s long stint on Tuesday morning, but remove a slow outlier on lap two and he improves massively to a 1m23.972s.Nissan e.dams is in turmoil thanks to its driver crisis. With two crucial days lost at Valencia, it also did not reach the upper echelons of long-run stints. But Buemi did get towards the sharp end in outright pace and FE’s most successful team (from its Renault days) should not be underestimated.As the second lowest manufacturer in the best-averages table, Jaguar could be in trouble. It did complete a race run straight off the bat with Nelson Piquet Jr on day one, but the average pace of that stint was well behind Audi’s similar effort, although things improve considerably looking at the adjusted table.Mitch Evans, Panasonic Jaguar Racing, Jaguar I-Type 3 with the new hyper boost LED lights on the haloPhoto by: Alastair Staley / LAT ImagesBut Jaguar did also complete the most laps of any team on 442, despite Mitch Evans losing two hours on the first morning to a battery issue. Given the factors that can influence FE testing times, this is another place where firm conclusions cannot be drawn for now.HWA, Mahindra and Dragon are the big unknowns as they simply did not complete sufficiently long runs to allow conclusions, despite their high places in the tables. At Mahindra, team boss Dilbagh Gill says the squad is “hitting our marks”, while Dragon – the only team yet to reveal its full driver line-up and 2018/19 livery – did not do a run above 13 laps.On the final afternoon, Formula 2 racers Maximilian Gunther and Fuoco each completed a series of flying laps on full power. If that was a shootout for the final Dragon seat, Gunther’s best lap won it by 0.337s.The ‘race that wasn’t a race’ was won by di Grassi. Given his prowess in the electric championship, that may not seem that remarkable, but the circumstances that produced FE’s first season-five chequered flag finish certainly were.First of all, it wasn’t really a race. At the request of the teams, FE and the FIA allocated a slot on the day-two afternoon schedule to test the 45-minute-plus-one-lap distance and trial the attack-mode race format. Active sensor loops were added at Turn 5 to simulate the need for drivers to run off-line to access the Gen2 cars’ higher-power mode in races. The cars also lined up in single file in the pitlane – Sims emerged first to take pole – and went off one-by-one.On lap one, Stoffel Vandoorne brought the full McLaren F1 experience to Valencia by stopping on track, and a few moments later Daniel Abt stuffed his Audi at the chicane on the main straight. Back to the pits they came, and the pack had to wait for nearly 45 minutes to allow Vandoorne’s car, which was declared ‘red’ (the electric systems still live – an FE first), to be recovered.Stoffel Vandoorne, HWA Racelab, VFE-05Photo by: Alastair Staley / LAT ImagesWhen they got going again, Buemi led for a while before stopping early. A number of other cars pulled off and the real contenders were DS Techeetah’s Vergne and Lotterer, and di Grassi and Sims. By the end, just di Grassi and Sims were left scrapping it out and when Sims lost momentum coming out of the final corner battling high battery temperatures, the race went to the Audi driver.Times for this session were deliberately not recorded – hence they are not factored into our average-run assessments.When it came to testing the attack-mode format, McNish explained that “it’s [about] making sure it’s armed at the correct point, making sure you run over everything at the correct point, and then also being sure the software works as well. That’s the loops in the ground but it’s also the software in the car, and a few people struggled with that.”Leaving Valencia, it does appear that the FE field has converged, with BMW, Audi and DS the likely frontrunners, and NIO and Venturi well up there too. There’s an understandable amount of paranoia over the new technology, but all teams are understood to have opted for the single-gear approach.As qualifying pace will be as key as ever in FE in 2018/19, BMW should head into the championship full of confidence, but the indications suggest a close, competitive season is coming up. 11Dragon13 laps1m32.194s* 6HWA16 laps1m25.201s 7Jose Maria LopezDragon1m17.830s Source: Electric Vehicle News You can’t read anything into testing”, “Valencia isn’t a street track”, “old or new tyres”, “power modes”, “track limits” – if it weren’t for the series-specific terms, one could have assumed that the Formula 1 paddock had stopped off at the Circuit Ricardo Tormo for a few days of extra testing before heading to the United States Grand Prix and not Formula E.With the new Gen2 cars – LED-halo-shod, looking gorgeous and sounding ever more like jets as their massive aerokits catch the wind – and their technology capable of lasting a whole race distance came an air of secrecy.But what was clear – despite the firm understanding that any analysis of anything that happened at Valencia last week was an utter hiding to nothing – is that many paddock sages think the field has converged ahead of FE’s fifth season. And if that proves to be the case when the racing gets under way in December, that is excellent news for the championship.Top testing times 6Felipe MassaVenturi1m17.696s Taking a look at the fastest overall times, it appears as if BMW Andretti comprehensively won the testing war – even if plenty were quick to note that this was as phony as ever. Not only did Antonio Felix da Costa take the fastest overall time of the test, but the squad, which is now BMW’s works FE entry with the Andretti crew running the operations team, topped all three days of running. Alexander Sims was quickest on days two and three.Alexander Sims BMW I Andretti Motorsports, BMW iFE.18Photo by: Alastair Staley / LAT ImagesDa Costa even went fastest in the wet morning session on Friday. So, BMW looks quick in all conditions – impressive stuff given Andretti finished last in the season-four standings. One observer from a rival squad reckoned BMW looks “mighty”.It’s no wonder the team feels pleased – and deservedly so.“We honestly came here with no expectations,” says team boss Roger Griffiths.“It was quite a pleasant surprise. We didn’t go out there to set a lap time [early on], we had a test programme – long runs, short-runs, stuff with different power levels. So, we did that and it wasn’t like we said ‘OK, we’re just going to for it’. I kept drilling into the drivers – ‘You have to leave some margin because we have no spares’. When we repeated it one-three [in the order] on Tuesday afternoon I said, ‘OK, perhaps, this is real’.”Dig into the fastest average race times – particularly fraught with peril this year given the huge increase in parameters that can influence times beyond powertrain efficiency (tyres that now degrade, different power levels and the new attack mode race format to access them, weather conditions – to name but a few) – and the competitive order gets more shaken-up.Average pace on longest runs 7Nissan21 laps1m25.222s Author Liberty Access TechnologiesPosted on October 28, 2018Categories Electric Vehicle Newslast_img read more

Hyundai Kona Electric Sales Soar Past 10000 In South Korea

first_imgSource: Electric Vehicle News Fully Charged Says Hyundai Kona Electric Is Brilliant Hyundai Kona Electric Charging Rates Compared: 39-kWh vs 64-kWh Hyundai Sold Record Number Of Plug-In Electric Cars In October 2018 Almost 3,000 in November alone in South Korea is a strong sign.Awaiting the global sales results of the Hyundai Kona Electric, we take a look at the South Korean market, which in November brings us a new record of Kona Electric sales.As it turns out, some 2,906 Kona Electric were sold (over 400 more than in October), which translates to more than 10,000 total sold since its introduction in May.Hyundai Kona Electric news The sales increase in South Korea encourages us that on the global level Hyundai will set a new record, hopefully beyond 5,000 per month.The Kona Electric accounted for more than half of total Kona sales (5,558) and 4.5% of total Hyundai car sales for the month of November in South Korea.Hyundai Kona Electric sales – November 2018 Author Liberty Access TechnologiesPosted on December 20, 2018Categories Electric Vehicle Newslast_img read more

China Is Building Too Many Electric Cars

first_img BloombergNEF Expects 2.6 Million EVs Sold Globally This Year, 57% In China According to the Fitch rating agency, China’s established automakers and start-ups have the capacity to produce 20 million electric cars in 2020. That’s 10 times the government’s sales target of 2 million units this year.The government’s restriction is aimed at new, smaller players – companies that are unable to produce at least 100,000 vehicles a year. These low-volume firms would be prevented from getting a manufacturing license.The Motor-Lite is produced by BAIC, which can make 300,000 EVs a year. (Photo: Bradley Berman)China is estimated to have about 500 EV start-ups. These companies are not the ones you’ve heard of – Byton, Nio or SF Motors – or the partnerships between major global car brands and large Chinese entities like BAIC, BYD, and Brilliant.Last year, I visited the Beijing Motor Show where I encountered hundreds of obscure EV brands. I was able to drive about a dozen of these cars.Zhidou, which makes the D2S, sold more than 72,000 EVs in 2017. (Photo: Bradley Berman)The Denza 500, produced in partnership with Daimler, was a quite decent all-electric SUV. But most of them were like the Motor-Lite two-passenger car and the Zhidou D2S, the type of glorified golf carts that were sold in the US before 2010. The Zhidou D2S – like the Fiat 500e, but smaller – was equipped with its own onboard fire extinguisher.I drove the Zhidou D2S. It came with a fire extinguisher. (Photo: Bradley Berman)Leaving quality and capability (or the fear of imminent death) aside, it’s remarkable to consider the world’s largest car market as being oversupplied with electric cars. “The move to curb EV investment ticks all the right boxes as all signs are showing that the segment is getting overheated,” Qian Kang, a Zhejiang-based auto entrepreneur told the Morning Post.The oversupply is occurring against the backdrop of Tesla breaking ground of its Shanghai plant this month. It’s expected to produce up to 500,000 cars per year eventually. In October 2018, Volkswagen began construction of its Shanghai plant that will produce up to 300,000 electric vehicles per year.Overall retail car sales in China fell by 5.8 percent in 2018 to 22.3 million cars. That was the first annual drop since 1990. On the other hand, 1.26 million so-called new energy vehicles were sold in China last year, representing a 61.7 percent jump in sales. China’s shift from older polluting cars to new electric cars is expected to continue growing this year. However, Bloomberg forecast EV sales in China to reach 1.5 million units in 2019, a more modest rate of growth than previous years. More Info On Tesla Model 3 Configuration In China China Electric Car Sales Soar To Almost 160,000 In December Source: Electric Vehicle News Author Liberty Access TechnologiesPosted on January 18, 2019Categories Electric Vehicle News China has 500 EV start-ups. The country can produce 20 million EVs a year.The Chinese government is preventing new electric car companies from starting up. The news – reported this week in the South China Morning Post – reveals that China is facing a potential glut of EV production.China EV Newslast_img read more

New Genesis Electric Concept To Debut In New York

first_img Tesla Model 3 Vs. Genesis G70: Video More Genesis News But then again, you can take this speculation with a grain of salt.While a new electric show car is an exciting bit on its own for Genesis, Donckerwolke added that an updated production-ready Genesis G90would also take center stage in its booth in New York.Meanwhile, Hyundai will showcase the new Sonata and the all-new Venue crossover. The latter is a newly-named crossover that the world has yet to see and will slot below the Kona.Source: CNET Roadshow However, there are no further details added to this statement, which is quite expected. Whether the show car will slot above or below the Essentia, we’ll surely know when the month of April comes. It isn’t too much to speculate, though, since several electric hypercars have been revealed since the Essentia was birthed. If Genesis would want to go head to head against names like the Pininfarina Battista, the New York Auto Show would be the best place to do it. Genesis Reveals Striking Essentia Electric Concept The confirmation came from Luc Donckerwolke, head of Hyundai Group design, in an interview with CNET Roadshow. It’s pretty straightforward. “You’ll have an electric show car for Genesis,” he said.center_img Genesis Brand Chooses Electrification Over Performance For Future Vehicles Will Genesis showcase an electric hypercar?Genesis is bound to do the same thing again at the upcoming New York Auto Show.The now-standalone company of Hyundai is bound to repeat history by showing new electric show car next month. To recall, the Korean luxury brand showcased the Essentia – an all-electric concept that’s confirmed to be going into production as Genesis’ priciest car. With its compelling looks and heart-stopping theoretical performance numbers (0-60 miles per hour in 3.0 seconds), it’s one of the showstoppers during last year’s New York Auto Show. Source: Electric Vehicle News Author Liberty Access TechnologiesPosted on March 31, 2019Categories Electric Vehicle Newslast_img read more

Burgess beats bug to bedevil wilting Hull

first_imgHull FC Burgess beats bug to bedevil wilting Hull Topics Sat 5 Apr 2008 07.34 EDT Share on WhatsApp First published on Sat 5 Apr 2008 07.34 EDT Share on Facebook Share on Facebook Andy Wilson at the KC Stadium Share on Twitter Support The Guardian Share via Email Rugby league Rugby league Since you’re here…center_img Share via Email Sam Burgess defied a violent stomach bug to lead Bradford to second in the Super League table and leave Hull’s coach, Peter Sharp, with a queasy feeling that is becoming all too familiar.With his team languishing in the bottom two, Sharp had admitted this week that they had to win this match and at Castleford next Friday to start their climb towards the top-six finish that was a minimum expectation at the start of the season.But after a bright start they were clearly second best in the second half, with Bradford’s young substitute Matt Cook making his first significant impact of a frustrating personal season to break an 8-8 deadlock in the 65th minute before Burgess made one try for Semi Tadulala and scored another himself to lift the Bulls above Warrington and Wigan on points difference.”What Sam did in the last quarter was outstanding when you think he shouldn’t really have played, he was so ill beforehand,” said Bradford’s coach, Steve McNamara. “That was an outstanding win for us because it’s only a matter of time before Hull FC turn their season around. Peter Sharp is a super bloke and a super coach, and I really feel for him.””We did a host of good things but at the moment we can’t sustain it for long enough,” said Sharp. “We just need to get through this patch and stick our nose out the other side.” The likeable Australian retains strong support from the players and the confidence of Hull’s directors, but admitted: “We need to win a game pretty soon.”Hull were near full strength last night, with Adam Dykes, Matt Sing and Garreth Carvell the only significant absentees, whereas the late withdrawal of David Solomona with a calf strain left Bradford without the four senior members of their first-choice pack plus a couple of backs.The home side were good value for a 6-0 advantage earned by a close-range effort from their tough Australian hooker Shaun Berrigan, but seemed to be disrupted by the loss to injuries of Richard Horne and Lee Radford midway through the first half. In contrast Bradford grew stronger as the game progressed, and it was no surprise when they pulled level in first-half stoppage-time, Chris Nero plucking a clever kick from Ben Jeffries out of mid-air to cross on the left for a try which Paul Deacon converted.Deacon nudged the Bulls ahead for the first time five minutes into the second half when Hull were caught offside in front of their posts. Hull equalised through a Danny Tickle penalty five minutes later, but only after being denied a second try by a touch judge who spotted a knock-on in the build-up to Todd Byrne beating Tadulala to cross in the corner.However, Hull continued to put themselves under pressure by pushing unnecessary passes inside their own half and one such error, from Byrne, handed Bradford the position for Cook to struggle over on the right. Tadulala’s score, which was superbly converted from near the touchline by Deacon, killed them off – and ensured another difficult week for Sharp.His unrelated namesake Jon also had a bad night, as his Huddersfield Giants team were beaten 20-16 by the in-form Catalans Dragons at the Galpharm Stadium.Hull FC Tony; Byrne, G Horne, Yeaman, Raynor; R Horne, Lee; Dowes, Berrigan, Cusack, Radford, Manu, Tickle.Interchange Washbrook, Wheeldon, Houghton, Thackray.Bradford Bulls Halley; Evans, Sykes, Hape, Tadulala; Jeffries, Deacon; Burgess, Godwin, Lynch, Nero, Finnigan, Langley.Interchange Harris, Feather, Cook, Kopczak.Referee B Thaler (Wakefield). Share on Pinterest Share on Messenger … we have a small favour to ask. The Guardian will engage with the most critical issues of our time – from the escalating climate catastrophe to widespread inequality to the influence of big tech on our lives. At a time when factual information is a necessity, we believe that each of us, around the world, deserves access to accurate reporting with integrity at its heart.More people are reading and supporting The Guardian’s independent, investigative journalism than ever before. And unlike many news organisations, we have chosen an approach that allows us to keep our journalism accessible to all, regardless of where they live or what they can afford. But we need your ongoing support to keep working as we do.Our editorial independence means we set our own agenda and voice our own opinions. Guardian journalism is free from commercial and political bias and not influenced by billionaire owners or shareholders. This means we can give a voice to those less heard, explore where others turn away, and rigorously challenge those in power.We need your support to keep delivering quality journalism, to maintain our openness and to protect our precious independence. Every reader contribution, big or small, is so valuable. Support The Guardian from as little as $1 – and it only takes a minute. Thank you. Super League XIII Bradford Bulls Share on LinkedIn Shares00 Super League Reuse this content Share on Twitter Hull FC 8-24 Bradfordlast_img read more

Iwelumo provides Wolves bite in Sheffield battle

first_imgChris Iwelumo celebrates scoring for Wolves. Photograph: PA/PA Iwelumo provides Wolves’ bite in Sheffield battle Shares00 Share on LinkedIn Tue 25 Nov 2008 19.01 EST Championship Mick McCarthy is still hobbling but Wolverhampton Wanderers show few signs of wobbling. While their manager is moving around his technical area on crutches, the legacy of ankle surgery, Wolves are proceeding towards the Premier League at rather greater speed. Sheffield United, ostensibly their promotion rivals, now languish 15 points behind after high-calibre finishes from Chris Iwelumo and Sylvan Ebanks-Blake. If Birmingham City, others with aspirations of top-flight football next season, are overcome on Saturday, Wolves will equal their club record of eight successive victories.That should have rendered McCarthy the most satisfied Yorkshireman at Bramall Lane but he said: “It is a nice position to be in but it means diddly squat.” The performance was greeted with more enthusiasm: “Lots of qualities are required to win football matches. Here, we were stoic and resolute in our defending but the quality of the three goals was excellent.”That is undeniable and it is in keeping with Wolves’ season that Iwelumo, who delivered a second successive double, outscored Ebanks-Blake. The target man has 15 of their combined haul of 26, statistics that reinforce McCarthy’s reputation for unearthing a bargain. Nevertheless, Iwelumo’s age – 30 – and status as an established Championship player meant he scarcely conformed to the Wolves manager’s usual criteria.However, his £400,000 fee has been swiftly repaid with the forward, infamously inaccurate in front of goal for Scotland, proving prolific. Both his strikes illustrated why. Accelerating on to Michael Kightly’s pass, Iwelumo evaded Sheffield United’s two central defenders, took the ball wide of their goalkeeper, Paddy Kenny, and finished calmly from an acute angle. Then, following sustained pressure from United, he secured victory with a volley of power and precision in equal measure. Ebanks-Blake emulated him with an unstoppable finish four minutes later, a rasping shot that flew past Kenny.Matthew Spring’s consolation goal, a crisply struck half-volley, was United’s only reward for a succession of shots. The most contentious was actually a corner. In United’s view Brian Howard’s in-swinger crossed the line before Wayne Hennessey clawed it back. The referee was unmoved by their appeals. “There’s no doubt about it, it was over the line,” said United’s assistant manager, Sam Ellis. “At 1-0 that makes it a different game. Two things affect games: goals and decisions.”Goalkeeping is a third factor. Both the replacement Hennessey and his predecessor on the pitch, Carl Ikeme, distinguished themselves with a series of saves. The latter was among four injured Wolves. McCarthy, no longer alone in the ranks of the walking wounded, may not consider imitation the sincerest form of flattery. First published on Tue 25 Nov 2008 19.01 EST Share via Email Wolverhampton Wanderers Topics Share on Facebook Share on Facebook Share on Twitter Share on Messenger Share via Email match reports Richard Jolly at Bramall Lane Share on Twitter Sheffield United Championship Share on Pinterest Share on WhatsApp Championship 2008-09 Reuse this contentlast_img read more

Friday Roundup

first_imgScrutiny alerts and updates, double standard, ripple, job description, new website, quotable and for the reading stack.  It’s all here in the Friday roundup.Scrutiny Alerts and UpdatesVimpelcom / TeliaSoneraAs highlighted in this recent post, when recently asked about the slowdown in 2015 DOJ corporate FCPA enforcement Andrew Weissmann (Chief of the DOJ Fraud Section) stated: “just wait three months, it might be a very different picture.”According to this report:“Vimpelcom “is set to announce a settlement with the US Department of Justice and Swiss and Dutch authorities that will be “just shy of a billion dollars.” […]  A source close to the DoJ, which does not comment publicly on individual cases, said it is expected that approximately three-quarters of the funds would go to the US government and the remainder to the European governments. […] [S]ources say [the Vimpelcom action] is a precursor for a much larger settlement coming down the line with TeliaSonera, the Swedish telecom operator.”See this prior post titled “The Burgeoning Uzbekistan Telecommunication Investigations.”SBM OffshorePrevious posts have highlighted SBM Offshore’s scrutiny including its disclosure in November 2014 that the DOJ informed the company “that it is not prosecuting the Company and has closed its inquiry” into allegations of improper conduct in Brazil and other countries.Earlier this week, the company disclosed:“[The DOJ] has informed SBM Offshore that it has re-opened its past inquiry of the Company and has made information requests in connection with that inquiry.  The Company is seeking further clarification about the scope of the inquiry.  The Company remains committed to close-out discussions on this legacy issue which the Company self-reported to the authorities in 2012 and for which it reached a settlement with the Dutch Public Prosecutor in 2014.”British American TobaccoThis previous Friday roundup highlighted the scrutiny surrounding British American Tobacco. Recently, several members of Congress sent this letter to Andrew Weissmann (Chief of the DOJ’s Fraud Section) stating in pertinent part:“We are deeply troubled by recent media reports alleging that British American Tobacco (BAT) conspired to bribe politicians and public health officials across Central and East Africa to block, weaken, and delay the passage and implementation of public health laws designed to protect people from the deadly effects of tobacco. We request the Department of Justice to investigate BAT’s alleged bribery to determine whether it violated the Foreign Corrupt Practices Act.”General CableThe company has been under FCPA scrutiny since approximately September 2014 and recently disclosed:“As previously disclosed, we have been reviewing, with the assistance of external counsel, our use and payment of agents in connection with, and certain other transactions involving, our operations in Angola, Thailand, India, China and Egypt (the “Subject Countries”). Our review has focused upon payments and gifts made, offered, contemplated or promised by certain employees in one or more of the Subject Countries, directly and indirectly, and at various times, to employees of public utility companies and/or other officials of state owned entities that raise concerns under the Foreign Corrupt Practices Act (“FCPA”) and possibly under the laws of other jurisdictions. We have substantially completed our internal review in the Subject Countries and, based on our findings, we have increased our outstanding FCPA-related accrual of $24 million by an incremental $4 million, which represents the estimated profit derived from these subject transactions that we believe is probable to be disgorged. We have also identified certain other transactions that may raise concerns under the FCPA for which it is at least reasonably possible we may be required to disgorge estimated profits derived therefrom in an incremental aggregate amount up to $33 million.The amounts accrued and the additional range of reasonably possible loss solely reflect profits that may be disgorged based on our investigation in the Subject Countries, and do not include, and we are not able to reasonably estimate, the amount of any possible fines, civil or criminal penalties or other relief, any or all of which could be substantial. The SEC and DOJ inquiries into these matters remain ongoing, and we continue to cooperate with the DOJ and the SEC with respect to these matters.”Qualcomm As highlighted in previous posts, Qualcomm has been under FCPA scrutiny for over four years and recently disclosed:“On March 13, 2014, the Company received a Wells Notice from the SEC’s Los Angeles Regional Office indicating that the staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company for violations of the anti-bribery, books and records and internal control provisions of the FCPA. The bribery allegations relate to benefits offered or provided to individuals associated with Chinese state-owned companies or agencies. The Wells Notice indicated that the recommendation could involve a civil injunctive action and could seek remedies that include disgorgement of profits, the retention of an independent compliance monitor to review the Company’s FCPA policies and procedures, an injunction, civil monetary penalties and prejudgment interest.A Wells Notice is not a formal allegation or finding by the SEC of wrongdoing or violation of law. Rather, the purpose of a Wells Notice is to give the recipient an opportunity to make a “Wells submission” setting forth reasons why the proposed enforcement action should not be filed and/or bringing additional facts to the SEC’s attention before any decision is made by the SEC as to whether to commence a proceeding. On April 4, 2014 and May 29, 2014, the Company made Wells submissions to the staff of the Los Angeles Regional Office explaining why the Company believes it has not violated the FCPA and therefore enforcement action is not warranted.On November 19, 2015, the DOJ notified the Company that it was terminating its investigation and would not pursue charges in this matter. The DOJ’s decision is independent of the SEC’s investigation, with which we continue to cooperate.”Double StandardWhile we wait for additional FCPA enforcement actions against financial service firms based on alleged improper internship and hiring practices in the mold of the BNY Mellon action, the Wall Street Journal reports:“Wall Street is emerging as a particularly dominant funding source for Republicans and Democrats in the presidential election, early campaign-finance reports filed with the Federal Election Commission show. So far, super PACs have received more than one-third of their donations from financial-services executives, according to data from the nonpartisan Center for Responsive Politics.”Separately, certain FCPA enforcement actions have been based on alleged “foreign officials” receiving speaking fees or excessive honorariums. Against this backdrop, here is the list of Hillary Clinton’s speaking fees for speeches delivered to Wall Street audiences after she left the State Department but while she was a presumptive presidential candidate.RippleOch-Ziff Capital Management has been under FCPA scrutiny since 2011. In this recent investor conference call, a company executive stated: “Uncertainty stemming from the FCPA investigation has also had some impact on investment decisions by certain LPs.”In other words, a ripple of FCPA scrutiny.To learn how FCPA scrutiny and enforcement has a range of negative financial impacts on a company beyond enforcement action settlement amounts, see “FCPA Ripples.”Job DescriptionWhat is the Assistant Deputy Chief of the DOJ’s Foreign Corrupt Practices Act Unit expected to do? See here for the job opening and expected duties.New WebsiteThe U.K. Serious Fraud Office recently unveiled a new website. Among the feature is a “current cases” page which specifically lists the following companies are under investigation for bribery/corruption offenses.Alstom Network UK Ltd & Alstom Power LtdENRC LtdGPT Special Project Management LtdInnovia Securency PTY LtdRolls-Royce PLCSoma Oil & GasQuotableIn this Corporate Crime Reporter interview, Crispin Rapinet (a partner at Hogan Lovells in London) states:“The danger of deferred prosecution agreements is the commercial temptation to deal with a problem that may or may not be in reality a real problem. If you pushed the prosecutor to actually establish that it is a criminal offense, it may not be that straight-forward. But the temptation for any corporate to deal with that risk through a commercial settlement which involves a sum of money and living with someone looking over your shoulder for a period of time is understandably great.Whether that, from a jurisprudential point of view, is the ideal world is questionable. You can see why people might take the view of — we don’t actually know whether these people have committed a criminal offense or not. But the power of the threat of the cost and time and management distraction associated with defending a claim, to say nothing of the ultimate risk if you are ultimately unsuccessful in your defense, is such that in the overwhelming majority of circumstances where these problems arise, the commercial temptation is to enter into a deferred or non prosecution agreement.”Spot-on.For The Reading StackAn informative read here from Jon Eisenberg (K&L Gates) regarding SEC civil monetary penalties.last_img read more

This Week On FCPA Professor

first_imgFCPA Professor has been described as “the Wall Street Journal concerning all things FCPA-related,” and “the most authoritative source for those seeking to understand and apply the FCPA.”Set forth below are the topics discussed this week on FCPA Professor.This post checks in on the FCPA enforcement action against Joseph Baptiste.As highlighted here, after years of waiting, a whistleblower in connection with the $519 million FCPA enforcement against Teva Pharmaceutical in late 2016 sued the SEC to speed up its award-decision making process.The Foreign Corrupt Practices Act has always been a law much broader than its name suggests and this post highlights an instructive example of an FCPA enforcement action that has nothing to do with foreign bribery.The DOJ Criminal Division released a guidance document titled “The Evaluation of Corporate Compliance Programs” (ECCP) and this post goes in-depth into the guidance. This post continues the analysis of the ECCP by highlighting various issues that caught my eye.Elevate your FCPA knowledge and practical skills at the FCPA Institute – Minneapolis on June 20-21. CLE credit is available. Can’t attend the live, in-person FCPA Institute? No problem, the FCPA Institute is also online and is the most comprehensive online FCPA training course available.last_img read more

Thompson Knight Opens San Francisco Office

first_img Username Lost your password? The Texas-based firm announced the opening of its second California office in the last six months with the addition of seven attorneys and other professional staff from San Francisco’s Ongaro Law Firm. The new office, which opened March 1, will be led by San Francisco litigator David Ongaro.“David and his team are experienced and effective litigators, and we have worked with them for common clients in California and elsewhere,” Emily Parker, the firm’s managing partner, said in a press release. “We saw this as an opportunity to join with lawyers who we know and trust to . . .You must be a subscriber to The Texas Lawbook to access this content. Remember mecenter_img Password Not a subscriber? Sign up for The Texas Lawbook.last_img read more

Scientists find novel tactic with potential for fighting medulloblastoma

first_imgJun 12 2018Scientists have a new tactic with potential for fighting medulloblastoma, the most common and most aggressive form of brain tumor in children.The results are scheduled for publication in Cancer Cell.Several emerging anticancer treatments are called “epigenetic therapies,” targeting the ways cancer cells shut off genes that could restrain their growth. The new tactic revives a protective gene called BAI1, by interfering with a protein that medulloblastoma cells use to silence BAI1.Reactivating BAI1, with a compound that penetrates into the brain, blocks medulloblastoma growth in mice. Senior author Erwin Van Meir, PhD, says this compound could be a basis for drug discovery and a valuable tool for attacking other types of cancer as well.”It was a surprise the molecule we identified was more specific than we thought.” Van Meir says. “This opens up a new area in epigenetic therapy.”Van Meir says that the Cancer Cell paper brings together research in his lab over the last 10 years. His team had originally been studying BAI1, because it was silenced in glioblastoma, another malignant brain tumor seen in adults. They had initially noticed that BAI1 is a regulator of angiogenesis, the process by which tumors attract new blood vessels.Related StoriesNanoparticles used to deliver CRISPR gene editing tools into the cellMother calls for protein shake regulation after daughter diesResearchers identify gene mutations linked to leukemia in children with Down’s syndrome”It turns out this is not actually BAI1’s most important function,” Van Meir says.BAI1 is also a “protector” of p53, which has a role in preventing many types of cancer by monitoring DNA damage and sensing other types of stress – p53 is sometimes called “guardian of the genome.”Senior research associate Dan Zhu, PhD, the first author of the paper, was able to work out how BAI1 (also known as ADGRB) protects p53: by holding back another protein, Mdm2, which tags p53 for degradation.In mice, the interactions between BAI1 and other genes linked to brain tumors weren’t clear until Van Meir and his colleagues started looking at models of medulloblastoma.”Once we delved into medulloblastoma, it became very obvious,” he says, adding that targeting BAI1 is likely to be effective across the four molecular sub-varieties of medulloblastoma.The compound that reactivates the BAI1 gene, called KCC-07, was identified in collaboration with the lab of Bill Nelson at Johns Hopkins. It interferes with MBD2, a protein that binds methylated DNA. Methylation is generally a modification that shuts genes off, and some epigenetic therapies aim to inhibit methylation, such as azacytidine/Vidaza, used against myelodysplastic syndrome. However, inhibiting the process of methylation turns many genes on or off – targeting just one DNA-binding protein could be more specific, Van Meir says.KCC-07 could inhibit medulloblastoma growth in cell culture and in mouse models, and “represents a promising chemical scaffold for further drug development,” the researchers conclude.Source: read more

GW introduces new summer program to advance cancer research

first_imgJun 26 2018The George Washington University (GW) School of Medicine and Health Sciences, in partnership with the GW Cancer Center, has launched a new summer program to advance cancer research through enhancing diversity in the field. The program is open to undergraduate students and is called the GW Summer Program Advancing Research on Cancer (GW-SPARC).”GW-SPARC will not only expose participants to cutting-edge research and contemporary cancer research techniques, but will also help foster understanding of health disparities and the impact of cancer in different communities,” said Alison Hall, PhD, associate dean for research workforce development at the GW School of Medicine and Health Sciences. “Most importantly, this program will help prepare diverse students for research careers, leading to discoveries that will improve our futures.”Related StoriesNew research links “broken heart syndrome” to cancerHow cell-free DNA can be targeted to prevent spread of tumorsNew protein target for deadly ovarian cancerThe program is open to U.S. undergraduate students from groups underrepresented in biomedical sciences. Preference will be given to sophomores and juniors so they might return for a second summer. Participants get the chance to live and work in the heart of Washington, D.C., just blocks from national monuments, museums, and entertainment.Through the program, students perform hands-on, mentored research in laboratories focused on cancer immunology and immunotherapy, cancer biology including targeted therapies and epigenetics, and cancer engineering and technology. Participants attend weekly workshops and seminars and at the end of the summer, and participate in a poster session. They also participate in a book club focused on the human impact of cancer; this year the book Everybody’s Got Something will be discussed.”At the GW Cancer Center, students will be mentored by researchers, using modern research techniques to look at issues like why African-American men are more heavily affected by prostate cancer, and many other aspects of cancer biology and health equity,” said Edward Seto, PhD, associate center director for basic science at the GW Cancer Center and King Fahd Professor of Cancer Biology at the GW School of Medicine and Health Sciences. “Our hope is that graduates from this summer program will go on to become active, motivated cancer researchers, ready to solve today’s most pressing problems, for those who need it most.”While applications are no longer being accepted for summer 2018, students can apply to the program for summer 2019 in winter 2018-19. For more information about GW-SPARC, visit”Diversity is critical to the future of all biomedical research – without a diverse workforce, how do we know if we’re asking the right questions? How do we include multiple approaches and perspectives?” said Hall. “Our goal is to support these students in their goals for graduate work, and invite them back to our programs at GW. We hope to have many programs like this at GW in the future in order to accomplish our goal of diversifying scientific research.” Source: read more

Manx Telecom unveils MT clearSound that improves clarity of mobile phone calls

first_imgMatthew Turner, CEO and Founder of Goshawk Communications, said: Source: Sep 20 2018Manx Telecom is delighted to announce the launch today on the Isle of Man of MT clearSound, a new, personal mobile phone product which dramatically improves the clarity of mobile phone calls. The product is available at no additional cost to PayMonthly customers on the Manx Telecom network.The technology behind the MT clearSound registered medical device is located within the network and requires no purchase or installation of specialist equipment by the user.A user completes a short online registration and a hearing assessment using any mobile phone on the Manx network, enabling MT clearSound to create a tailored individual hearing profile.This fine tunes all incoming and outgoing telephone calls to meet the user’s personal hearing needs. The profile can be changed at any time by the user if their requirements change, for example with the adoption of a new hearing aid or purchase of a new mobile phone.MT clearSound will help people suffering from moderate to severe hearing loss to communicate and to maintain the art of conversation, enabling and empowering them to use their mobile phone with more confidence.During the clinical trial, 80% of respondents said they felt stress-free while using the service. According to 89% of the trialists, the product should be available to everyone who has a hearing need.MT clearSound is the first such product worldwide and has a huge potential addressable market, being suitable for both people with varying levels of hearing loss and those wanting to enhance the quality of their mobile phone conversations in general.The introduction of the product on the Isle of Man, where it was researched, trialled and developed by Vannin Ventures, Manx Telecom’s business incubator, with Goshawk Communications, the lead investment in its portfolio, is just the latest example of the island serving as a test-bed for innovation; but the technology will also be made available off island as soon as 2019, when BT will leverage its EE mobile network to launch the technology, targeting the eleven million UK consumers who experience hearing loss.Related StoriesMalaria drug may help those with hereditary hearing loss finds studyStudy brings clarity about milk intake for children with Duarte galactosemiaPeople under age 50 with hearing loss more likely to misuse alcohol and drugsMT clearSound was inspired by Goshawk founder Matthew Turner’s own experiences with hearing loss.Deaf since the age of four, his determination to create a solution lead to the creation of MT clearSound, which is based on the algorithms of Professor Brian Moore of the University of Cambridge, one of the world’s leading authorities on auditory perception.The product is backed by further medical and audiology professionals in the UK and on the Isle of Man, including Doctor Michael Stone, Senior Research Fellow in Audiology / Hearing Sciences at University of Manchester, who have worked closely with Goshawk and Manx Telecom on the ground-breaking mobile phone technology.Gary Lamb, CEO of Manx Telecom, said: MT clearSound will empower people suffering from a moderate to severe hearing loss, and every mobile user seeking greater call clarity, to use their mobile phones with greater confidence. The launch of MT clearSound in the UK next year in partnership with BT has the potential to change the lives of millions of people and is further evidence of Manx Telecom’s investment in innovation and technology.” I created a ‘hearing aid in the sky’ because of my frustration with telecoms companies who did not understand people with hearing loss. Engaging with Manx Telecom was very different – it was easy to reach the decision-makers and the work environment was very open. We know MT clearSound can make a huge difference to people’s lives. Ideally this should set the Global Standard – that for me would be a wonderful achievement.”last_img read more

Roadside trees trap asthmainducing pollutants

first_img Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Roadside parkways in cities provide mixed benefits when it comes to improving local air quality, suggests new studies from Finland.  Email Roadside trees trap asthma-inducing pollutants By Barbra Rodriguez Aug. 23, 2017 , 2:58 PM PORTLAND, OREGON—More trees mean cleaner air, right? Not necessarily, suggests a new study looking at the wooded areas next to roadways. Instead, lines of trees known as “greenbelts” might actually trap a common pollutant from vehicle exhaust—nitrogen dioxide (NO2)—boosting on-the-ground levels of the gas up to 21%. That could make breathing hard for bikers and pedestrians with asthma or other respiratory diseases.For decades, cities from Shanghai, China, to London have lined their avenues with trees to beautify downtown areas—and, planners hoped, cut air pollution. To test that idea, urban ecologist Heikki Setälä from the University of Helsinki and his team measured air quality in and around 10 greenbelts in the Helsinki metropolitan area in the summer and winter of 2016, focusing on NO2. The greenbelts were all downwind from heavily trafficked roadways, including some major freeways. As a control, the team recorded levels of NO2 in adjacent open fields at the same distance from the road that were also downwind.After taking 40-plus days of measurements, the team found that along busy roads in front of greenbelts, summertime NO2 levels were on average 14% higher than in the fields. Inside the greenbelts they were about 12% higher. In the winter, the roadside concentration of NO2 was 21% higher and the interior levels were 10% higher, they reported here this month at the annual meeting of the Ecological Society of America.center_img Sign up for our daily newsletter Get more great content like this delivered right to you! Country Steve Halama on unsplash Click to view the privacy policy. Required fields are indicated by an asterisk (*) In the study, which also appeared online 9 August in Urban Climate, Setälä suggests that lack of wind might be the culprit. The dense tree canopies likely cause it to stall out, making it more difficult for pollutants to disperse—a situation that gets worse in winter. That scenario makes sense, says physiological ecologist Tom Whitlow of Cornell University, who has conducted wind tunnel and field experiments on how particle pollutants interact with leaves and trees.The effect resembles a smoker holding an umbrella that traps rising cigarette fumes. The higher levels alongside roadways are particularly worrisome, Setälä says, because sidewalks and trails are often built there. “Nobody has scientific evidence that this increased [long-term] concentration [of NO2] is really harmful,” he says, “but of course if they’re elevated, that’s not a good sign.” Laboratory studies on the short-term effects of much higher concentrations of the gas suggest it can harm the lungs of asthmatics and those with a chronic form of lung disease.Sara Janhäll, an urban air researcher from the Swedish National Road and Transport Research Institute in Linköping, says the team did a good job of designing its study. However, she wishes they had quantified leafy surfaces within greenbelts to clarify how well they passively captured the gas. Measuring the conversion of NO2 into nitrogen monoxide, a sunlight-driven process, would have also indicated how much more of the gas could be present in shadier greenbelts near pollution sources.When it comes to pollution, trees aren’t all bad. Another study led by Setälä’s team found that trees in 25 urban forests and parks in Baltimore, Maryland, reduced ground-level ozone by about 9% compared with adjacent open spaces, they report in an upcoming issue of Atmospheric Environment. However, when it came to NO2 concentrations, the wooded settings—which were far from busy roads—were no better than those in open spaces. Together, Janhäll says, the results serve as a reminder that—in the right place—plants really can improve air quality. “We can use vegetation much more than we do, but the design can be totally wrong, and then you won’t get an air pollution-reducing effect.”last_img read more

New evidence that dengue antibodies trigger lifethreatening infections

first_img Sign up for our daily newsletter Get more great content like this delivered right to you! Country Email New evidence that dengue antibodies trigger life-threatening infections Eva Harris (far right) has led a dengue study in Nicaragua that for more than 12 years has regularly taken blood samples from children. Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Click to view the privacy policy. Required fields are indicated by an asterisk (*)center_img Alejandro Belli/PLOS Pathogens By Jon CohenNov. 2, 2017 , 2:10 PM It’s a disease theory fit for a spy novel: Protective antibodies can turn double agent, teaming up with the dengue virus to make an infection more severe, even life-threatening. First proposed more than 40 years ago, antibody-dependent enhancement (ADE) has won over many doubters but still has impassioned skeptics. Now, a finding from a large, long-term study in Nicaraguan children adds compelling evidence that ADE is real, occurring when people previously infected with dengue—and with the right level and type of dengue antibodies still in their blood—become infected again.“It wasn’t my life mission to prove or disapprove ADE,” says molecular biologist Eva Harris of the University of California, Berkeley, who started the study to better understand dengue epidemiology and pathology. “We kind of stumbled into it. And I never was really convinced until these data.”Dengue, spread by mosquitoes, sickens up to 100 million people each year, mostly in tropical regions of the world. The virus has four “serotypes,” each of which triggers a unique antibody response. Someone infected for the first time with any of the serotypes typically has a mild, flulike disease that causes fever and muscle pains but does not require hospitalization. But those who become infected with a second serotype later are at risk of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), which can cause massive fluid loss, organ failure, and death. What is unclear is how, exactly, the first infection makes the second one more severe. “That’s where the field has been stuck for decades,” Harris says. ADE advocates say the pre-existing antibodies are to blame, but others contend that T cells, innate immunity, and genetics also play important roles.The ADE hypothesis, backed by test tube and animal data, builds on the fact that an antibody to the first dengue serotype can bind to the virus, but not strongly enough to “neutralize” it. This binding antibody/virus complex more easily enters host cells, allowing the virus to copy itself at even higher levels. The intensified infection leads the immune system to storm the body with chemical messengers called cytokines, ultimately increasing the likelihood of blood vessels leaking, causing hemorrhage and shock.ADE doesn’t always occur when people are infected with an additional dengue serotype, say the theory’s supporters, because the mechanism is complex. Exposure to dengue virus triggers a mix of binding and neutralizing antibodies—and ADE requires the mix to be just right. If a person’s pre-existing dengue antibodies are low, there aren’t enough binding antibodies to help the virus enter host cells. And if a person’s antibody levels are high, they’ll have enough neutralizing ones that can “cross-react” to the second infection and slow it down. The same thing happens if a person has been infected with two or more serotypes. But people enter the ADE “danger zone” when their levels are somewhere in the middle, Harris says.To do the study, Harris and her team enrolled more than 8000 children between the ages of 2 and 14 in Managua and analyzed dengue antibodies found in their blood samples repeatedly taken over a 12-year period. Participants were asked to come to the study clinic if they had a fever; those kids were bled again and referred to a hospital if necessary.More than 600 children came down with symptomatic dengue, and 44 of them developed DHF/DSS. An analysis of 41,302 blood samples taken from the entire study at different time points found that a child who had an intermediate antibody level and became infected again had a 7.64 times higher risk of being in the small group that developed DHS/DSS, researchers report today in Science.“[The study is] truly impressive and a good example of how investments in long-term studies pay off,” says Aravinda de Silva, a virologist who studies dengue at the University of North Carolina School of Medicine in Chapel Hill. “I think this paper will put to rest whether antibodies can enhance dengue.”It hasn’t, however. Timothy Endy, a dengue researcher at the State University of New York Upstate Medical University in Syracuse, notes that the assay Harris’s group used did not distinguish between binding and neutralizing antibodies—or even the different serotypes. “This study falls short,” says Endy, who says it’s “simplistic” and “overstated” to link ADE to specific levels of pre-existing dengue antibodies. “ADE is still a theory that invites rigorous science and investigation.”Harris agrees that more work needs to be done to characterize the specific antibodies behind the phenomenon. “This paper is about a seroepidemiological finding,” she says. “It has the potential to be taken to next step that has a finer resolution of exactly what kind of antibodies are being measured, and that’s where we want to take it.”Even the father of the dengue-ADE hypothesis, Scott Halstead of the Uniformed Services University of the Health Sciences in Bethesda, Maryland, says the new work doesn’t offer definitive proof of ADE. “If you’re going to say enhanced infection is occurring, you need direct evidence that infection was enhanced,” Halstead says. One way of doing that, he suggests, is by showing increased levels of virus in children infected for the second time. Still, Halstead says he’s “delighted” to see the new data that support ADE. Alternative theories are “fantasies” that have wasted research money, he says.Whether the new finding has a practical application remains unclear. Halstead, Harris, and many other researchers have raised concerns that a dengue vaccine produced by Sanofi Pasteur may, in fact, be triggering ADE in some recipients. Clinical trials showed increased hospitalization from dengue in young children who received the shot, which is now licensed in at least 11 affected countries. The World Health Organization recommends that it only be used in kids over the age of 9, and only in areas where dengue incidence is high.Halstead insists the increased hospitalization rate is due to ADE—which Sanofi Pasteur disputes—and says the vaccine should not be given to people who test negative for dengue antibodies. Harris agrees. And knowing that intermediate antibody levels increase the risk of DHF/DSS could prove useful in the testing of future vaccines by showing who might be in what she calls the danger zone.That, not surprisingly, is debated, too.*Correction 17 November, 5:30 p.m.: This story has been corrected to reflect Scott Halstead’s comments on who should receive the vaccine.last_img read more